 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol
IDs
|
|
|
| |
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
|
|
|
|
Phase III
|
|
|
|
A6181037
NCT00130897
|
|
| |
Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery
|
|
|
|
Phase III
|
|
|
|
ECOG-E2805
E2805, CALGB-E2805, SWOG-E2805, CAN-NCIC-E2805, NCT00326898
|
|
| |
Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
|
|
|
|
Phase III
|
|
|
|
VEG107769
NCT00387764
|
|
| |
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
|
|
|
|
Phase III
|
|
|
|
A6181114
NCT00428220
|
|
| |
Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer
|
|
|
|
Phase III
|
|
|
|
MRC-RE05-SORCE
MRC-RE05-SORCE, EUDRACT ID 2006-006079-19, EU-20734, NCT00492258, SORCE, ISRCTN38934710
|
|
| |
Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)
|
|
|
|
Phase III
|
|
|
|
12750
NCT00478114
|
|
| |
Study Comparing Bevacizumab + Temsirolimus Vs Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
|
|
|
|
Phase III
|
|
|
|
3066K1-3311
NCT00631371
|
|
| |
Axitinib (Ag 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
|
|
|
|
Phase III
|
|
|
|
A4061032
AXIS TRIAL, NCT00678392
|
|
| |
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
|
|
|
|
Phase III
|
|
|
|
108844
COMPARZ, NCT00720941
|
|
| |
Sequential Study to Treat Renal Cell Carcinoma
|
|
|
|
Phase III
|
|
|
|
09072008-13772
EudraCT 2008-005011-18, NCT00732914
|
|
